U.S. stocks lower as investors rotate out of tech ahead of Jackson Hole
Director Gary Blackford of Avanos Medical Inc (NYSE:AVNS) recently purchased shares of the company’s common stock, according to a Form 4 filing with the Securities and Exchange Commission. On August 13, 2025, Blackford acquired a total of 60,000 shares in two separate transactions, with a total value of $659300. The timing appears strategic, as InvestingPro analysis indicates the stock is currently undervalued, with a market cap of $513.21 million and strong free cash flow yield of 18%.
The purchases were executed at weighted average prices ranging from $10.975 to $10.995. Specifically, Blackford directly purchased 20,000 shares at a weighted average price of $10.975, in the price range of $10.94 to $11.01, for a total value of $219,500. Additionally, 40,000 shares were purchased indirectly through a trust at a weighted average price of $10.995, in the price range of $10.98 to $11.04, for a total value of $439,800. Following these transactions, Blackford directly owns 91,593 shares of Avanos Medical. The company maintains a healthy balance sheet with a current ratio of 2.64 and moderate debt levels. For deeper insights into AVNS’s financial health and additional ProTips, visit InvestingPro, where you’ll find comprehensive analysis and detailed research reports.
In other recent news, Avanos Medical Inc. reported its second-quarter 2025 earnings, surpassing market expectations. The company achieved an adjusted earnings per share (EPS) of $0.17, exceeding the forecast of $0.15. Avanos Medical’s revenue also outperformed projections, reaching $175 million compared to the anticipated $165.8 million. These results highlight a positive earnings surprise for the quarter. Despite these favorable financial outcomes, other factors led to a decline in the company’s stock price, which is not discussed here. There were no reports of mergers or acquisitions, nor were there any analyst upgrades or downgrades mentioned in the recent developments. Investors will likely continue to monitor Avanos Medical for further updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.